Skip to main content

Articles By Jack Cush, MD

lupus.GN_.jpg

Lupus Nephritis Despite Low Level Proteinuria

By Jack Cush, MD
27 January 2021

Kidney International reports on a series of systemic lupus erythematosus (SLE) patients, who despite inactive urinary sediment and low level proteinuria, had a high rate of glomerulonephritis (GN) proven by renal biopsy; moreover, the LN was not predicted by laboratory abnormalities.

Read Article
Gout Podagra big toe

Urate Lowering Therapy During Acute Gout

By Jack Cush, MD
26 January 2021

Acute gout has its well defined protocols, and most state that urate lowering therapy (ULT) should be continued; but does ULT affect outcomes in an acute gout attack?

Read Article
burnout work overworked

Rheumatologists Rank 2nd in Physician Burnout

By Jack Cush, MD
26 January 2021

The 2021 Medscape Survey on Physician burnout ranks rheumatology second, just behind Critical Care medicine. The survey included over 12,000 physcians from 20 specialties. While 42% of MDs claimed to be burnt-out, Rheumatologists claimed this 50% of the time. The top 3 this year were Critical care (51%), Rheumatology (50%) and infectious disease (49%).

Read Article
pills-384846__180.jpg

Protective Effects of Colchicine in Non-Hospitalized COVID-19

By Jack Cush, MD
25 January 2021

A press release from Montreal Heart Institute announced that the COLCORONA clinical trial provided evidence of the protective effect of colchicine; demonstrating a 21% reduced risk of death or hospitalizations in patients with COVID-19 compared to placebo. COLCORONA trial was a contact-less, randomized, double-blind, placebo-controlled study of 4,488 non-hospitalized patients from Canada, the U.S., Europe, South America and South Africa.

Read Article
FDA%20approved_1.jpg

Voclosporin FDA Approved for Lupus Nephritis

By Jack Cush, MD
24 January 2021

On January 22nd, the FDA approved voclosporin (Lupkynis) for use in adults with active lupus nephritis; voclosporin is a calcineurin-inhibitor immunosuppressant indicated for use in combination with a background immunosuppressive therapy. FDA approval was based on data from the pivotal AURORA Phase 3 study and the AURA-LV Phase 2 study, which demonstrated the ability of voclosporin to significantly improve LN outcomes after 52 weeks of followup in SLE nephritis patients receiving background standard of care therapies like MMF, and low dose steroids. 

Read Article
podcast logo

RheumNow Podcast – Don’t Hold the Benlysta, Take the Vaccine (1.22.2021)

By Jack Cush, MD
22 January 2021

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com, with more than a dozen items to discuss on this week's podcast.

Read Article
COVID Test Antibody

NEJM: Early Combo Monoclonal Antibody Therapy in COVID-19

By Jack Cush, MD
21 January 2021

NEJM has published the interim analysis of the REGN-COV2 trial, wherein an antibody cocktail reduced viral loads with less clinical consequences. 

Read Article
COVID infection mask

Combo Anti-Spike Protein Antibody for Mild to Moderate COVID-19

By Jack Cush, MD
21 January 2021

JAMA has published the BLAZE-1 study, showing significant SARS-CoV-2 viral load reduction at day 11 and less COVID-19 progression when combination anti-spike monoclonal antibody therapy (bamlanivimab and etesevimab) was given to mild to moderate, non-hospitalized COVID-19 patients.

Read Article
TB.EMimage.CDC_.jpg

Low Risk of TB with Secukinumab

By Jack Cush, MD
20 January 2021

JAMA Dermatology has reported on a longitudinal cohort study of 12,319 secukinumab (SEC) treated patients (psoriasis, psoriatic arthritis, or ankylosing spondylitis); no new cases of active tuberculosis (TB) and very few cases of latent tuberculosis infection (LTBI) were found. 

Read Article
ILD damage fibrosis path

Mortality Risk in Rheumatoid Lung Patients

By Jack Cush, MD
20 January 2021

A Medicare claims analysis of rheumatoid arthritis (RA) patients showed that RA-associated interstitial lung disease (RA-ILD) was seen in nearly 5% of patients and was found to increase mortality risks, including respiratory and cancer mortality not explained by other factors.

Read Article
×